Publication | Open Access

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Hematological MalignancyOncologyHematologyMyeloid NeoplasiaPrimary AnalysisMedicineRadiation OncologyHigh-risk Multiple MyelomaHealth Sciences